
Opinion|Videos|July 29, 2024
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the impact of dose modifications or interruptions on treatment outcomes with CDK4/6 inhibitors in the adjuvant setting?
- What has your experience been with toxicities and their management impacting patient adherence to CDK4/6 inhibitors in the adjuvant setting, and what strategies have you used to help improve this?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5














































